Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 402-130-7 | CAS number: 106246-33-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- September - December 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 402-130-7
- EC Name:
- -
- Cas Number:
- 106246-33-7
- Molecular formula:
- C21 H28 Cl2 N2
- IUPAC Name:
- 4-[(4-amino-2-chloro-3,5-diethylphenyl)methyl]-3-chloro-2,6-diethylaniline
- Details on test material:
- - Name/code : P5367
- Appearance : Off-white to yellowish powder
- Storage : At ambient temperature in the dark
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature in the dark
- Stability under test conditions: stable
- Solubility and stability of the test substance in the solvent/vehicle: stable
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga, Sulzfeld, F.R.G., Germany
- Weight at study initiation: body weights of the males ranged from 142 to 162 g and those of the females from 111 to 137 g
- Housing: gang housing (6 animals/sex/group/cage) in polycarbonate cages
- Diet: Standard laboratory diet (RMH-0. pellet diameter 9 mm, Hope Farms, Woerden,
- Water: ad libitum
- Acclimatisation: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20 - 21°C
- Humidity: mean 60-70%
- Lightning: artificial light sequence was 12 hours light (7:00 to 19:00), 12 hours dark (19:00 to 7:00).
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- mixed with diet
- Details on oral exposure:
- Method of administration: feeding test (test item mixed with diet); for diet preparation, see "any other information on materials and methods"
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Based on analysis of the stability of the test substance in the diets of the pilot study, it was decided to prepare the diets for the 28-day study only once, i.e. 1 day prior to study start. The sequence for diet mixing and pelleting was control group (no test substance), followed by low dose, medium dose and high dose group. The weighed out test substance was mixed with a fraction of the diet in a Kenwood mixer for 6 minutes resulting in a 3% premix. In a professional dough mixer the appropriate amount of diet was moistened with 7% (w/w) fresh tap-water and was subsequently supplemented by the premix.
DIET PREPARATIONS:
Dosage (ppm) Diet (kg) Test substance (g)
0 25 0
100 25 2.5
300 25 7.5
1000 25 25.0 - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 ppm
- Remarks:
- = 0 mg/kg bw/day nominal in diet
- Dose / conc.:
- 100 ppm
- Remarks:
- = 100 mg/kg bw/day nominal in diet
- Dose / conc.:
- 300 ppm
- Remarks:
- = 300 mg/kg bw/day nominal in diet
- Dose / conc.:
- 1 000 ppm
- Remarks:
- = 1000 mg/kg bw/day nominal in diet
- No. of animals per sex per dose:
- MALES:
- 6 animals at 0 ppm
- 6 animals at 100 ppm
- 6 animals at 300 ppm
- 6 animals at 1000 ppm
FEMALES:
- 6 animals at 0 ppm
- 6 animals at 100 ppm
- 6 animals at 300 ppm
- 6 animals at 1000 ppm - Control animals:
- yes, plain diet
- Positive control:
- no positive control tested
Examinations
- Observations and examinations performed and frequency:
- Cage-side observations:
With the exception of days 0, 7, 21 and 28, cage-side observations were performed once daily on working days (beginning on day 1) as well as weekends until terminal sacrifice on day 28. Any deviations from normal were recorded. In particular, attention was paid to changes of skin, fur, eyes, mucous membranes, respiratory system. faeces and general appearance. On working days a mortality check was performed in the eveni
Physical examinations:
Once a week, i.e. on days 0 (prior to dosing), 7, 14, 21 and 28 the animals underwent a physical examination. In addition to the parameters mentioned for cage-side observations, particular attention was paid to ears. mouth, urogenital region, anus, abnormal masses, gait, general state and behaviour.
Body weights and food consumption
Individual body weights were determined immediately prior to the first dosing (day 0), weekly thereafter (days 7, 14, 21 and 27), and on day 28 prior to sacrifice (fasted body weight). Individual food consumption was recorded weekly (days 7, 14, 21 and 27) and was expressed as grams food consumed per animal and as grams food consumed per 100 grams body weight per day.
Haematology and clinical chemistry
Prior to sacrifice on day 28 the animals were anaesthetized with ether and the abdominal cavity was opened. Blood was collected via the abdominal aorta by means of an infusion set provided with a winged needle (Mediwing, Argyle. Sherwood Medical Industries, Tullamore, Ireland). For haematology approximately 1.5 ml of blood were collected directly into vials containing 0.03 ml of di- and tripotassium EDTA (30% (W/V), pH 7.4). Immediately thereafter blood samples were collected in clot tubes for clinical chemistry. The vials intended for haematology were rotated at 90 rpm until transportation to 'Bergschot Centrum voor Onderzoek CBCO)' in Breda. The Netherlands for analysis. The maximum period between blood collection and transport to BCO was 5.5 hours. The approximately 3 ml blood samples intended for clinical chemistry were allowed to clot during 30-60 minutes. The serum was separated by centrifugation and transferred into another tube. Serum samples were kept on ice until analysis by BCO.
The red blood cells of the samples were counted using a "Coulter" blood cell counter, while their size distribution was determined using the "Haemalog 6000" (Technicon). Measurement of haemoglobin concentration, counting of white blood cells and subsets thereof, i.e. lymphocytes, neutrophils, large unstained cells, monocytes, eosinophils and basophils, and the counting of thrombocytes were also performed using the Haemalog 6000. The haematocrit values were determined using a microcentrifuge. All clinical chemical parameters were measured in serum samples using a "Parallel" clinical chemistry analyzer. - Sacrifice and pathology:
- On completion of blood collection the animals were sacrificed by exsanguination. Subsequently a full gross necropsy was performed which included examination of the external surface and openings, and the cranial, thoracic and abdominal cavities with their contents. Liver, adrenals, kidneys, spleen and testes were removed and weighed.
The following tissues were removed and preserved in 10% formalin: Liver. spleen, kidneys, adrenals. heart and macroscopically abnormal tissues. Fixed organs and tissues from animals of the control and high dose group were embedded in paraffin, sectioned, stained with haematoxylin and azophloxine, and examined microscopically. - Statistics:
- Means with standard deviation were calculated for all quantitative parameters. Statistical procedures were carried out for quantitative data suspected of changes and were based on a one-way analysis of variance supplemented with a t-test (Biodata Handling with Microcomputers, Barlow. 1983). One-way analysis of variance (F-test) was used to analyse the results for overall effects of dosage. Significant differences between control and individual dosages were also assessed by using the F-test where P < 0.05 was accepted as the lowest level of significance . The total food consumption represents the group mean of the sum of the individual food consumption over the entire period (day 7, 14. 21 and 27). whereas the body weight gain was obtained by calculating the group mean of the mean individual body weight gain (obtained from a linear regression analysis for the individual body weight over the entire period, i.e. day 0, 7, 14, 21 and 27).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- With respect to the group mean haematology data no evident test substance related effect was observed, except for a statistically significant (P<0.05) increase of thrombocytes in the high dose group (i.e. 18% and 20% increase for males and females, respectively). The remaining haemometric values were comparable for the control group and the treatment groups. In addition, the obtained values were in general agreement with those reported in the literature (Charles River Laboratories. Technical Bull~tin, 1984). Incidental abnormal values were obtained with the following animals. Animals A4 and C4 showed an increased haematocrit value: the latter animal also had an increased number of erythrocytes. Animal B8 showed an increase of erythrocytes and haemoglobin and decreased mean cellular volume (MCV) and MCV/RBC values. With respect to the group mean clinical chemistry data no
statistically significant test substance related effect was observed in sera of male or female animals, with the exception of the calcium concentration that was increased in female animals of the high dose group (6% increase; P=0.05). The obtained values were in general agreement with those reported in the literature. Serum aspartate aminotransferase and alanine aminotransferase were increased in animals A11 and C10. - Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute and relative liver and adrenal weights were increased in both sexes in the top dose group only.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Macroscopic examination of all animals at necropsy revealed no evident test substance related gross abnormalities. with exception of dilated renal pelvis (observed once in the low dose group and twice in the high dose group; considered as a congenital abnormality in this rat strain), petechiae of the stomach (observed once in the control group), enlarged adrenals (observed once in low dose group and twice in the high dose group) and petechiae of the thymus (observed once in the high dose group). With the exception of enlarged adrenals in animals of the high dose group, the above findings were considered incidental and not test substance related.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Microscopic examination of the liver of animals dosed at 1000 ppm revealed hypertrophy of centrilobular liver cells.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Details on results:
- SUMMARY:
CLINICAL OBSERVATIONS:
No deaths and no clinical signs of toxicity.
LABORATORY FINDINGS:
Platelet counts were increased in both sexes in the top dose group and serum calcium was slightly increased in top dose females.
EFFECTS IN ORGANS:
Absolute and relative liver and adrenal weights were increased in both sexes in the top dose group only. The only effect seen microscopically was hypertrophy of the centrilobular cells of the liver.
Effect levels
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- haematology
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 100 ppm
- Organ:
- bladder
Applicant's summary and conclusion
- Conclusions:
- Based on the findings it was concluded that a dietary exposure level of 300 ppm (equivalent to 38 mglkglday for males and females combined) represents the No Effect Level for P5367 in the present study.
- Executive summary:
The study was performed 1987 as GLP-test following EC-test method B.7 on Sprague-Dawley rats. Application of test material was via diet, the dose levels were 0, 100, 300 and 1000 ppm. No deaths and no clinical signs of toxicity were noted. Laboratory findings included increased platelet counts in both sexes in the top dose group and slightly increased serum calcium in top dose females. Absolute and relative liver and adrenal weights were increased in both sexes in the top dose group only. The only effect seen microscopically was hypertrophy of the centrilobular cells of the liver. In conclusion, the NOEL was found to be 300 ppm (= 38 mg/kg/day).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.